MX2016014768A - Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd. - Google Patents

Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd.

Info

Publication number
MX2016014768A
MX2016014768A MX2016014768A MX2016014768A MX2016014768A MX 2016014768 A MX2016014768 A MX 2016014768A MX 2016014768 A MX2016014768 A MX 2016014768A MX 2016014768 A MX2016014768 A MX 2016014768A MX 2016014768 A MX2016014768 A MX 2016014768A
Authority
MX
Mexico
Prior art keywords
dasotraline
adhd
treatment
dosage
exhibit
Prior art date
Application number
MX2016014768A
Other languages
English (en)
Inventor
D Loebel Antony
S Koblan Kenneth
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of MX2016014768A publication Critical patent/MX2016014768A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen formas de dosificación y regímenes de tratamiento que emplean dasotralina para tratar el trastorno de hiperactividad con déficit de atención (ADHD). Las composiciones descritas en la presente exhiben potencial de abuso.
MX2016014768A 2014-05-13 2015-05-12 Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd. MX2016014768A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461992619P 2014-05-13 2014-05-13
PCT/US2015/030357 WO2015175523A1 (en) 2014-05-13 2015-05-12 Dosage of dasotraline and method for treatment of adhd

Publications (1)

Publication Number Publication Date
MX2016014768A true MX2016014768A (es) 2017-03-06

Family

ID=54480549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014768A MX2016014768A (es) 2014-05-13 2015-05-12 Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd.

Country Status (10)

Country Link
US (1) US10076503B2 (es)
EP (1) EP3143000A4 (es)
JP (1) JP2017515849A (es)
KR (1) KR20170005088A (es)
CN (1) CN106660937A (es)
AU (1) AU2015259346A1 (es)
CA (1) CA2948839A1 (es)
IL (1) IL248847A0 (es)
MX (1) MX2016014768A (es)
WO (1) WO2015175523A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092496A1 (en) * 2018-10-31 2020-05-07 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
WO2004024669A1 (en) 2002-09-16 2004-03-25 Sepracor, Inc. Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
DK2506842T3 (en) * 2009-12-04 2015-02-23 Sunovion Pharmaceuticals Inc Formulations, salts and polymorphs of transnorsertraline and their applications

Also Published As

Publication number Publication date
KR20170005088A (ko) 2017-01-11
EP3143000A1 (en) 2017-03-22
AU2015259346A1 (en) 2016-12-08
EP3143000A4 (en) 2017-12-13
JP2017515849A (ja) 2017-06-15
US10076503B2 (en) 2018-09-18
WO2015175523A1 (en) 2015-11-19
CA2948839A1 (en) 2015-11-19
CN106660937A (zh) 2017-05-10
IL248847A0 (en) 2017-01-31
US20170266134A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
GB2541571A (en) Pharmaceutical compositions
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
IL253979B (en) Methods, preparations and kits for cancer treatment
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
PL3153169T3 (pl) Sposób leczenia nowotworu, kompozycja farmaceutyczna i zestaw medyczny w postaci opakowania
MY192927A (en) Fused bicyclic compounds for the treatment of disease
SG10201709322PA (en) Apparatus for treatment of waste gas and method for treating the same
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
IL252011A0 (en) Methods and compositions especially for the treatment of attention deficit disorder
EP3252019A4 (en) Method for treating wastewater, and activator for treating wastewater
EP3187579A4 (en) Composition, support, wastewater treatment system, wastewater treating method, deodorization method, and batch wastewater treating method
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
TW201613587A (en) Medical treatments based on anamorelin
PH12017501864A1 (en) Compositions and methods for treating autism
MX379622B (es) Compuestos espirociclicos
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
PH12017500602A1 (en) Methods for treating ocular conditions
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EP4480577A3 (en) Structured elements and methods of use
PH12016501838A1 (en) Compounds and their methods of use